The trial will evaluate the safety and effectiveness of a next-generation vaccine administered through a nasal spray or ...

A nasal vaccine for COVID-19 – based on technology developed at Washington University in St. Louis – is poised to enter a phase 1 clinical trial in the U.S. after an investigational new drug ...

Confusion between approved injectable epinephrine products and unapproved nasal solutions has prompted a warning to ...

A nasal spray that contains esketamine — a potent derivative of ketamine — can now be taken on its own to treat adults with ...

Johnson & Johnson's nasal spray received US FDA approval The nasal spray is used for the treatment of major depressive disorder The drug brought in sales of $780 million in 2024 The US Food and Drug ...

A one-time nasal spray has been approved by the Food and Drug Administration as a standalone treatment for depression.

Spravato is now the first stand-alone therapy for treatment-resistant depression, for patients who haven't responded to oral antidepressants.

WEDNESDAY, Jan. 22, 2025 (HealthDay News) -- The U.S. Food and Drug Administration has approved Spravato (esketamine) CIII nasal spray for adults living with major depressive disorder who have had an ...

Got a tip? Send it to The Daily Beast here. ADVERTISEMENT ADVERTISEMENT ...

WEDNESDAY, Jan. 22, 2025 (HealthDay News) -- The U.S. Food and Drug Administration has approved Spravato (esketamine) CIII nasal spray for adults living with major depressive disorder who have had ...

The nasal spray Spravato, which is made from the drug esketamine, had been approved in 2019 for patients who failed to respond to at least two oral antidepressants. However, it had to be used in ...

The Food and Drug Administration (FDA) approved Johnson & Johnson’s ketamine-derived nasal spray to help millions of U.S. patients suffering from severe depression. Spravato, approved as a ...